Valencene post-treatment exhibits cardioprotection via inhibiting cardiac hypertrophy, oxidative stress, nuclear factor- κB inflammatory pathway, and myocardial infarct size in isoproterenol-induced myocardial infarcted rats; A molecular study

Eur J Pharmacol. 2022 Jul 15:927:174975. doi: 10.1016/j.ejphar.2022.174975. Epub 2022 Apr 22.

Abstract

The growing burden of myocardial infarction (MI) becomes a major global health issue that is accountable for considerable mortality worldwide. Hence, it is obligatory to develop a new treatment for MI having lesser side effects. Cardiac hypertrophy, oxidative stress, and inflammatory pathways play crucial roles in the pathogenesis of MI. This investigation established the anti-cardiac hypertrophic, antioxidant, anti-inflammatory, and myocardial infarct size limiting effects of valencene. Rats were induced MI by isoproterenol (100 mg/kg body weight) and then treated with valencene and cardiac sensitive markers, cardiac hypertrophy, oxidative stress, markers of inflammation, nuclear factor- κB inflammatory pathway, and myocardial infarct size was estimated/determined. The serum cardiac diagnostic markers, cardiac hypertrophy, conjugated dienes, markers of inflammation, pro-inflammatory cytokines, and myocardial infarct size were significantly (P < 0.05) increased by isoproterenol. Further, antioxidant enzymes and anti-inflammatory cytokine gene were significantly (P < 0.05) decreased in the heart. The 2, 3, 5-triphenyl tetrazolium chloride dye staining revealed a larger infarct size. Moreover, histological results of myocardial infarcted rat's cardiac tissue revealed separation of cardiac muscle fibers, necrosis, and inflammatory cells. Post-treatment with valencene (12 mg/kg body weight) orally, daily, for two weeks to isoproterenol-induced myocardial infarcted rats reversed all above said structural, biochemical, molecular, and histological parameters investigated, by its anti-cardiac hypertrophic, antioxidant, anti-inflammatory, and myocardial infarct size limiting effects. Thus, valencene is a potential candidate for inhibiting cardiac hypertrophy, oxidative stress, nuclear factor- κB inflammatory pathway, and myocardial infarct size and exhibited cardioprotection in MI.

Keywords: Isoproterenol; Lipid peroxidation; Myocardial infarction; Oxidative stress; Troponin-I; Valencene.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents
  • Antioxidants* / metabolism
  • Biomarkers / metabolism
  • Body Weight
  • Cardiomegaly / chemically induced
  • Cardiomegaly / drug therapy
  • Cardiomegaly / metabolism
  • Inflammation / metabolism
  • Isoproterenol / pharmacology
  • Myocardial Infarction* / chemically induced
  • Myocardial Infarction* / drug therapy
  • Myocardial Infarction* / metabolism
  • Myocardium / metabolism
  • Myocytes, Cardiac / metabolism
  • NF-kappa B / metabolism
  • Oxidative Stress
  • Rats
  • Rats, Wistar
  • Sesquiterpenes

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Biomarkers
  • NF-kappa B
  • Sesquiterpenes
  • valencene
  • Isoproterenol